• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    22nd Century Group Reports Third Quarter 2025 Financial Results

    11/4/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email

    Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash

    VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability

    MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights.

    "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of our VLN® products are now available for purchase, our store count is increasing every month, and we are securing new distribution agreements to expand our reach.

    "As the leader in the Tobacco Harm Reduction Movement, we believe that all tobacco companies should complement their full nicotine products with a set of low nicotine products within their brand families. Our technology roadmap makes this possible, with short time to market and at any scale required, through both Partner VLN® and licensing capabilities, allowing every tobacco company to become fully aligned with the FDA's Low Nicotine Mandate instead of resisting. By doing so, tobacco companies can for the first time truly deliver on their claims of supporting tobacco harm reduction efforts. As important, smoking consumers can access a new way to change in their smoking habit with a form factor that they are accustomed to, the combustible cigarette, but without the highly addictive nicotine that drives addiction," said Larry Firestone, CEO of 22nd Century Group.

    "Additionally, we are now in the best financial position of the past two years and have begun the growth phase of our company. With the $9.5 million settlement of our prior insurance claims from the Grass Valley facility fire in 2022 and a debt free balance sheet, we now have a well-funded cash position on which to build the market, both directly and in partnership with our growing list of brand partners adopting VLN® based products. We have recently announced further expansion of both state authorizations and store counts across our VLN® based products, with stocking orders underway now to support our continued expansion."

    "We are also exploring other ways to bring VLN® based products to the forefront of the industry and make low nicotine a fundamental part of the fabric of the tobacco industry."

    Third Quarter 2025 Financial Results (compared to Second Quarter 2025, except as noted)

    All figures reported below reflect continuing operations, excluding discontinued operations related to the sale and exit of the Company's hemp/cannabis business in late 2023, except as noted.

    ●Net revenues decreased slightly to $4.0 million from $4.1 million.
    ●Gross profit (loss) was $(1.1) million, compared to $(0.6) million.
    ●Operating expenses were $2.2 million, decreased from $2.3 million.
    ●Operating loss increased to $3.2 million, compared to $3.0 million.
    ●Consolidated net income increased to $5.5 million, compared to net loss of $3.4 million, reflecting the $9.5 million insurance settlement in discontinued operations.
    ●Adjusted EBITDA loss was $2.9 million, compared to a loss of $2.6 million.
    ●Ended the third quarter 2025 with cash of $4.8 million.
      

    Recent Business Highlights

    ●Strong balance sheet improvement, ending third quarter 2025 with no outstanding debt and an additional $9.5 million in cash received in November 2025 from the insurance settlement.
    ●Expanded market access to both VLN® and Partner VLN® brand launches, new natural style cigarette products and increased state authorizations as part of the relaunch of the Company's branded products. State authorizations now include:



     ○22nd Century VLN® – 45 States
     ○Smoker Friendly VLN® – 38 States
     ○Pinnacle® VLN® – 38 States
     ○Smoker Friendly – 46 States
     ○ Pinnacle® – 43 States



    ●Delivered first shipments of Pinnacle® VLN® products to top-5 convenience store chain stores across 12 states; began store rollout to approximately 1,000 initial stores as part of a staged launch initiative.
    ●Continued to advance negotiations with new customers to expand VLN® distribution and launch additional VLN® partner brands, further diversifying the reduced nicotine content product category.
    ●Implemented margin expansion, cost savings and efficiency initiatives of our manufacturing operations to align from the historically low margin CMO volume to our higher margin branded products, including VLN® and Partner VLN®.
    ●Advanced plans for 100mm format VLN® cigarettes, plus international combustible products tailored to consumer preferences in those markets, as well as additional filtered cigar products.
      

    Third Quarter 2025 Product Line Net Revenues

    ●Cigarette net revenues were $2.5 million, from $2.7 million in the third quarter of 2025, reflecting an increase in certain customer pricing incentives, offset by increased CMO volumes. Additional expansion of new natural style cigarette products launched in 2025 will continue to accelerate revenue and margin growth in this category.
    ●Filtered cigar net revenues were stable at $1.3 million, reflecting ongoing volume from remaining CMO customers.
    ●Cigarillo distribution net revenues were negligible and reflect the time necessary for initial stocking orders to be sold through our distributors before additional reorders are fulfilled in later 2025.
    ●VLN® cigarette net revenues were $0.2 million, reflecting initial stocking order activity of partner VLN® products, offset by customer returns and product exchanges to the new VLN® branding. Additional partner brand agreements are in progress as part of a relaunch of its VLN® reduced nicotine content products.
      

    Balance Sheet

    ●The Company reported zero long-term debt at quarter end, having extinguished the remaining $3.9 million of its senior secured debt in full.
    ●Cash and equivalents were $4.8 million at quarter end.
    ●Subsequent to the quarter end, the Company received $9.5 million in insurance proceeds due from the previously announced settlement of its Grass Valley Fire claim.
      

    Conference Call

    22nd Century will host a live webcast today at 8:00 a.m. E.T. to discuss its third quarter 2025 financial results and business highlights. The live and archived webcast will be accessible in the Events section on 22nd Century's Investor Relations website at https://ir.xxiicentury.com/events.

    Summary Financial Results

    (dollars in thousands, except per share data)

      Three Months Ended 
      September 30,  Change 
      2025  2024  $  % 
    Revenues, net $4,011  $5,946   (1,935)  (32.5)
    Gross loss $(1,059) $(588)  (471)  80.1 
    Operating loss $(3,212) $(3,377)  165   (4.9)
    Net loss from continuing operations $(3,763) $(3,585)  (178)  5.0 
    Basic and diluted loss per common share from continuing operations $(1.06) $(848.84)  847.78   (99.9)
    Adjusted EBITDA (a) $(2,885) $(3,178)  293   9.2 



      Nine Months Ended 
      September 30,  Change 
      2025  2024  $  % 
    Revenues, net $14,050  $20,361   (6,311)  (31.0)
    Gross loss $(2,303) $(1,147)  (1,156)  100.8 
    Operating loss $(8,763) $(9,858)  1,095   (11.1)
    Net loss from continuing operations $(10,333) $(11,248)  915   (8.1)
    Basic and diluted loss per common share from continuing operations $(7.94) $(4,297.69)  4,289.75   (99.8)
    Adjusted EBITDA (a) $(7,845) $(9,247)  1,402   15.2 
                     

    (a) Adjusted EBITDA is a non-GAAP financial measure. Please see "Notes Regarding Non-GAAP Financial Information" for additional information regarding our use of non-GAAP financial measures. Refer to Tables A at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.

    Summary Product Line Results

    (in thousands)

      Three Months Ended 
      September 30,       
      2025  2024  Change 
      $  Cartons  $  Cartons  $  Cartons 
    Contract Manufacturing                        
    Cigarettes  2,520   345   4,078   156   (1,558)  189 
    Filtered Cigars  1,282   168   1,664   253   (382)  (85)
    Cigarillos  -   -   204   30   (204)  (30)
    Total Contract Manufacturing  3,802   513   5,946   439   (2,144)  74 
    VLN®  209   4   -   -   209   4 
    Total Product Line Revenues  4,011   517   5,946   439   (1,935)  78 



      Nine Months Ended 
      September 30,       
      2025  2024  Change 
      $  Cartons  $  Cartons  $  Cartons 
    Contract Manufacturing                        
    Cigarettes  10,249   1,370   10,942   416   (693)  954 
    Filtered Cigars  3,704   498   8,593   1,249   (4,889)  (751)
    Cigarillos  88   14   756   120   (668)  (106)
    Total Contract Manufacturing  14,041   1,882   20,291   1,785   (6,250)  97 
    VLN®  9   1   70   1   (61)  0 
    Total Product Line Revenues  14,050   1,883   20,361   1,786   (6,311)  97 
                             

    About 22nd Century Group, Inc.

    22nd Century Group is pioneering the tobacco harm reduction movement by enabling smokers to take control of their nicotine consumption.

    Our Technology is Tobacco

    Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

    Our Products

    We created our flagship product, the VLN® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

    VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC.

    Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

    Learn more about VLN® at tryvln.com.

    Cautionary Note Regarding Forward-Looking Statements

    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (iii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 20, 2025 and Quarterly Reports on Form 10-Q on May 13, 2025, August 14, 2025, and November 4, 2025. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

    Notes regarding Non-GAAP Financial Information

    In addition to the Company's reported results in accordance with generally accepted accounting principles in the United States of America ("GAAP"), the Company provides EBITDA and Adjusted EBITDA.

    In order to calculate EBITDA, the Company adjusts net (loss) income by adding back interest expense (income), provision (benefit) for income taxes, and depreciation and amortization expense. Adjusted EBITDA consists of EBITDA adjusted by the Company for certain non-cash and/or non-operating expenses, including adding back equity-based employee compensation expense, restructuring and restructuring-related charges such as impairment, acquisition and transaction costs, and other unusual or infrequently occurring items, if applicable, such as inventory reserves and adjustments, gains or losses on disposal of property, plant and equipment, and gains or losses on investments.

    The Company believes that the presentation of EBITDA and Adjusted EBITDA are important financial measures that supplement discussion and analysis of its financial condition and results of operations and enhances an understanding of its operating performance. While management considers EBITDA and Adjusted EBITDA to be important, these financial performance measures should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating (loss) income, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company's measurement of Adjusted EBITDA may not be comparable to those of other companies.

    Investor Relations & Media Contact

    Matt Kreps

    Investor Relations

    22nd Century Group

    [email protected]

    214-597-8200

    22nd CENTURY GROUP, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    (amounts in thousands, except share and per-share data)

      September 30, 2025  December 31, 2024 
    ASSETS        
    Current assets:        
    Cash and cash equivalents $4,846  $4,422 
    Accounts receivable, net  2,993   1,698 
    Inventories  2,906   2,015 
    Insurance recoveries  9,500   768 
    GVB promissory note, net  —   500 
    Prepaid expenses and other current assets  2,678   1,068 
    Current assets of discontinued operations held for sale  —   1,051 
    Total current assets  22,923   11,522 
    Property, plant and equipment, net  2,452   2,773 
    Operating lease right-of-use assets, net  767   1,639 
    Intangible assets, net  6,210   5,724 
    Other assets  15   15 
    Total assets $32,367  $21,673 
             
    LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY        
    Current liabilities:        
    Notes and loans payable - current $368  $254 
    Current portion of long-term debt  —   1,500 
    Operating lease obligations  163   261 
    Accounts payable  2,598   2,401 
    Accrued expenses  2,234   1,021 
    Accrued litigation  —   768 
    Accrued payroll  140   318 
    Accrued excise taxes and fees  3,399   2,038 
    Deferred income  79   20 
    Other current liabilities  1,231   100 
    Current liabilities of discontinued operations held for sale  333   1,281 
    Total current liabilities  10,545   9,962 
    Long-term liabilities:        
    Operating lease obligations  644   1,437 
    Long-term debt  —   5,165 
    Other long-term liabilities  74   1,097 
    Total liabilities  11,263   17,661 
             
    Mezzanine equity:        
    Series A convertible preferred shares, $0.00001 par value; 9,650 shares issued and outstanding at September 30, 2025 and 0 at December 31, 2024, respectively  2,734   — 
    Total mezzanine equity  2,734   — 
             
    Shareholders' equity:        
    Common stock, $.00001 par value, 500,000,000 shares authorized, 6,987,290 shares issued and outstanding at September 30, 2025 and 31,727 at December 31, 2024, respectively        
    Common stock, par value  —   — 
    Capital in excess of par value  414,487   397,883 
    Accumulated deficit  (396,117)  (393,871)
    Total shareholders' equity  18,370   4,012 
    Total liabilities, mezzanine equity and shareholders' equity $32,367  $21,673 



    22nd CENTURY GROUP, INC.


    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (Unaudited)

    (amounts in thousands, except share and per-share data)

      Three Months Ended  Nine Months Ended 
      September 30,  September 30, 
      2025  2024  2025  2024 
    Revenues, net $4,011  $5,946  $14,050  $20,361 
    Cost of goods sold  2,557   3,102   8,304   11,184 
    Excise taxes and fees on products  2,513   3,432   8,049   10,324 
    Gross loss  (1,059)  (588)  (2,303)  (1,147)
    Operating expenses:                
    Sales, general and administrative  1,849   2,547   5,766   7,814 
    Research and development  193   240   583   915 
    Other operating expense (income), net  111   2   111   (18)
    Total operating expenses  2,153   2,789   6,460   8,711 
    Operating loss from continuing operations  (3,212)  (3,377)  (8,763)  (9,858)
    Other income (expense):                
    Other income (expense), net  (33)  100   (207)  439 
    Interest income, net  16   3   46   26 
    Interest expense  (534)  (311)  (1,443)  (1,828)
    Total other income (expense), net  (551)  (208)  (1,604)  (1,363)
    Loss from continuing operations before income taxes  (3,763)  (3,585)  (10,367)  (11,221)
    (Benefit) provision for income taxes  —   —   (34)  27 
    Net loss from continuing operations $(3,763) $(3,585) $(10,333) $(11,248)
                     
    Discontinued operations:                
    Income (loss) from discontinued operations before income taxes $9,252  $(172) $8,087  $640 
    Provision for income taxes  —   —   —   — 
    Income (loss) from discontinued operations $9,252  $(172) $8,087  $640 
                     
    Net income (loss) $5,489  $(3,757) $(2,246) $(10,608)
    Comprehensive income (loss) $5,489  $(3,757) $(2,246) $(10,608)
                     
    Net income (loss) $5,489  $(3,757) $(2,246) $(10,608)
    Deemed dividends  —   (3,677)  —   (7,711)
    Net income (loss) available to common shareholders $5,489  $(7,434) $(2,246) $(18,319)
                     
    Basic income (loss) per share:                
    Basic loss per common share from continuing operations $(1.06) $(848.84) $(7.94) $(4,297.69)
    Basic income (loss) per common share from discontinued operations $2.61  $(40.77) $6.21  $244.44 
    Basic loss per common share from deemed dividends $—  $(870.65) $—  $(2,946.25)
    Basic income (loss) per common share $1.55  $(1,760.26) $(1.73) $(6,999.50)
                     
    Diluted income (loss) per share:                
    Diluted loss per common share from continuing operations $(1.06) $(848.84) $(7.94) $(4,297.69)
    Diluted income (loss) per common share from discontinued operations $0.78  $(40.77) $1.99  $137.00 
    Diluted loss per common share from deemed dividends $—  $(870.65) $—  $(2,946.25)
    Diluted income (loss) per common share $(0.28) $(1,760.26) $(5.95) $(7,106.94)
                     
    Weighted average shares outstanding:                
    Basic  3,541,337   4,223   1,301,656   2,617 
    Diluted  11,888,488   7,182   4,070,266   4,670 



    Table A – Reconciliations of Non-GAAP Measures


    (dollars in thousands, except share and per-share data)

    Below is a table containing information relating to the Company's Net loss, EBITDA and Adjusted EBITDA for the three and nine months ended September 30, 2025 and 2024, including a reconciliation of these Non-GAAP measures for such periods.

      Quarter Ended 
      September 30, 
      Amounts in thousands ($000's) 
      except share and per share data 
      (UNAUDITED) 
            $ Change 
      2025  2024  fav / (unfav)1 
    Net loss from continuing operations $(3,763) $(3,585) $(178)
    Interest (income)/expense, net  518   308   210 
    Provision (benefit) for income taxes  —   —   — 
    Amortization and depreciation  234   249   (15)
    EBITDA $(3,011) $(3,028) $17 
    Adjustments:            
    Restructuring and impairment  —   (23)  23 
    Inventory write-down  —   —   — 
    Change in fair value of derivative liabilities  —   (23)  23 
    Change in fair value of warrant liabilities  33   (100)  133 
    Equity-based employee compensation expense  93   (4)  97 
    Adjusted EBITDA $(2,885) $(3,178) $293 
                 
    Adjusted EBITDA loss per common share $(0.81) $(752.58) $751.77 
    Weighted average common shares outstanding - basic and diluted  3,541,337   4,223     



      Year Ended 
      September 30, 
      Amounts in thousands ($000's) 
      except share and per share data 
      (UNAUDITED) 
            $ Change 
      2025  2024  fav / (unfav)1 
    Net loss from continuing operations $(10,333) $(11,248) $916 
    Interest (income)/expense, net  1,397   1,802   (405)
    Provision (benefit) for income taxes  (34)  27   (61)
    Amortization and depreciation  693   762   (69)
    EBITDA $(8,277) $(8,657) $380 
    Adjustments:            
    Restructuring and impairment  —   (348)  348 
    Inventory write-down  —   431   (431)
    Change in fair value of derivative liabilities  —   (482)  482 
    Change in fair value of warrant liabilities  207   (424)  631 
    Equity-based employee compensation expense  225   233   (8)
    Adjusted EBITDA $(7,845) $(9,247) $1,402 
                 
    Adjusted EBITDA loss per common share $(6.03) $(3,533.20) $3,527.17 
    Weighted average common shares outstanding - basic and diluted  1,301,656   2,617     
                 

    1Fav = Favorable variance, which increases EBITDA and Adjusted EBITDA; Unfav = unfavorable variance, which reduces EBITDA and Adjusted EBITDA



    Primary Logo

    Get the next $XXII alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    22nd Century Group Reports Third Quarter 2025 Financial Results

    Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights. "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of o

    11/4/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Announces Receipt of $9.5 Million from Settlement of Insurance Claim

    MOCKSVILLE, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced receipt of $9.5 million in cash proceeds pursuant to its previously announced settlement agreement for all claims with its insurer for business interruption related to the Grass Valley incident that occurred in November 2022. "This settlement closes another chapter of our past and solidifies our company's transition from a clean-up to entering a growth phase. We now have a balance sheet with meaningful cash resources that will allow u

    10/28/25 5:07:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Launches VLN® with Major C-Store Chain, New Marketing Collateral, Continues to Expand State Authorizations

    VLN® to Commence Sales at Circle K Locations in Illinois, Now Authorized in 45 States and Counting MOCKSVILLE, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the launch of VLN® reduced nicotine content cigarettes at approximately 140 Circle K locations in Illinois. VLN® cigarettes are now authorized for sale in 45 states, with 5 remaining states pending. As part of the launch, the Company also unveiled new marketing and consumer education material featuring the full suite of VLN® combustible

    10/23/25 7:45:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

    Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    7/21/22 9:12:19 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on 22nd Century Group with a new price target

    Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    6/15/22 7:42:24 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Roth Capital initiated coverage on 22nd Century Group with a new price target

    Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

    3/8/22 9:21:23 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    5/31/24 4:05:20 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    1/8/24 8:04:11 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Keys David N was granted 2,118 shares (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    10/6/25 5:01:38 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Keys David N

    3 - 22nd Century Group, Inc. (0001347858) (Issuer)

    8/5/25 4:55:06 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Johnson Anthony L. was granted 2,472 shares, increasing direct ownership by 35,314% to 2,479 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    3/12/25 5:37:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    SEC Filings

    View All

    SEC Form 424B5 filed by 22nd Century Group Inc.

    424B5 - 22nd Century Group, Inc. (0001347858) (Filer)

    11/4/25 5:00:17 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by 22nd Century Group Inc.

    10-Q - 22nd Century Group, Inc. (0001347858) (Filer)

    11/4/25 7:31:01 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    11/4/25 6:06:37 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Announces Resignation of John Miller as President of Tobacco

    Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

    5/30/24 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

    BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

    9/12/22 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Reports Third Quarter 2025 Financial Results

    Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights. "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of o

    11/4/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Second Quarter 2025 Financial Results

    VLN® Early Adoption Commercial Activity Expands with Two Partner Brand Launches in Progress – Smoker Friendly and Pinnacle Commenced Pinnacle VLN® Stocking Shipments for Almost 1,000 Locations of Top-5 C-Store Customer, Additional Locations to Come Significantly Expanded State Authorizations for both Reduced Nicotine Content and Conventional Products High Margin Branded Products Business Model Set to Grow Profitably MOCKSVILLE, N.C., Aug. 14, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for th

    8/14/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports First Quarter 2025 Financial Results

    Sales Increase Approximately 50% Sequentially as 2025 Growth Strategy Drives New Sales Activity with Both Internal and External Brand Assets Across Multiple Categories  Preparing First VLN® Partner Brand Shipments with Smoker Friendly and Others Filings Made for New Reduced Nicotine Content and Conventional Product Authorizations in All 50 States Launch of Smoker Friendly Black Label – Tobacco and Water natural style cigarettes MOCKSVILLE, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announ

    5/13/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by 22nd Century Group Inc.

    SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

    10/23/24 7:27:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care